John Stuelpnagel, Entrepreneur
0:00 A sense about biological complexity
7:26 How do you defend the industry’s accomplishments to others?
14:22 What are some of the new “writing" applications?
22:55 Will there be more resistance to the “writer” than the “reader”?
32:02 A faster uptake by industry in this new phase
Not many people have had quite the same view on the genomics revolution as John Stuelpnagel. He co-founded Illumina, Ariosa, and Fabric Genomics (formerly Omicia). And he’s the Chairman of Fabric, 10X Genomics, and Inscripta. And not all had the foresight John did that biology would turn out to be so complex.
John is our guest today to preview and describe what he calls the new “writing” phase of genomics, which he says is already underway.
“Genomics has been mostly—and I hope I don’t offend the audience—a passive science. We’re limited by our cohort sets that we can put together. I think the next level of biological discovery is going to be where you can actively perturb the system—it’s called a cell—and then ask what kind of phenotype did we generate."
It’s a fascinating look ahead from one who not only founded some genomics tools companies, but founded several of THE genomics tools companies.